Concepedia

Daniel Moj

DM

Statistics

Publications

6

Citations

343

H-Index

6

Active since

2016

Affiliations

Saarland University(Current)

Heidelberg University

Bayer (Germany)

Daniel Moj is an author at Saarland University specializing in pharmacokinetic modeling, pharmacology, and pharmacokinetics.

Publications per year

2016–2019

6

Publications

6

PBPK Models for CYP3A4 and P‐gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin

Nina Hanke, Sebastian Frechen, Daniel Moj et al. · CPT Pharmacometrics & Systems Pharmacology · 2018 · 162 citations · Full text

, , +17

A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug–Drug Interactions

Xia Li, Sebastian Frechen, Daniel Moj et al. · Clinical Pharmacokinetics · 2019 · 63 citations · Full text

, , +17

Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug–Drug Interactions and Co-medication Regimens

Daniel Moj, Nina Hanke, Hannah Britz et al. · The AAPS Journal · 2016 · 42 citations

, , +14

A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification

Daniel Moj, Hannah Britz, Jürgen Burhenne et al. · Cancer Chemotherapy and Pharmacology · 2017 · 29 citations · Full text

, , +16

A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin—integration of in vitro results, Phase I and Phase II data and model application for drug–drug interaction potential analysis

Nina Hanke, Michael Teifel, Daniel Moj et al. · Cancer Chemotherapy and Pharmacology · 2017 · 24 citations

, , +17

1–5 of 6